Liu P, Liu Y, Ke CN, Li WS, Liu YM, Xu S. Therapeutic effect of autologous concentrated growth factor on lower-extremity chronic refractory wounds: A case report. World J Clin Cases 2021; 9(18): 4797-4802 [PMID: 34222450 DOI: 10.12998/wjcc.v9.i18.4797]
Corresponding Author of This Article
Shi Xu, PhD, Associate Professor, Department of Burn and Plastic Surgery, Shenzhen Longhua District Central Hospital, No. 187 Guanlan Avenue, Longhua District, Shenzhen 518110, Guangdong Province, China. xushi_cn@163.com
Research Domain of This Article
Dermatology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Jun 26, 2021; 9(18): 4797-4802 Published online Jun 26, 2021. doi: 10.12998/wjcc.v9.i18.4797
Therapeutic effect of autologous concentrated growth factor on lower-extremity chronic refractory wounds: A case report
Po Liu, Yang Liu, Chang-Neng Ke, Wei-Shan Li, Yue-Ming Liu, Shi Xu
Po Liu, Yang Liu, Chang-Neng Ke, Wei-Shan Li, Yue-Ming Liu, Shi Xu, Department of Burn and Plastic Surgery, Shenzhen Longhua District Central Hospital, Shenzhen 518110, Guangdong Province, China
Author contributions: Liu P and Liu Y collected the clinical data, reviewed the literature, and contributed to manuscript drafting; Ke CN and Li WS collected the clinical data; Liu YM and Xu S directed and corrected the study; Liu P and Liu Y contributed equally to this work; all the authors read and approved the manuscript for publication.
Supported byShenzhen Longhua District Science and Innovation Bureau for Key Laboratory Construction, No. 20160919A0410022; and Shenzhen Longhua District Science and Innovation Bureau Fund for Medical Institutions, No. 2020038 and No. 2017136.
Informed consent statement: Written informed consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: The authors declare that they have no conflict of interest to report.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Shi Xu, PhD, Associate Professor, Department of Burn and Plastic Surgery, Shenzhen Longhua District Central Hospital, No. 187 Guanlan Avenue, Longhua District, Shenzhen 518110, Guangdong Province, China. xushi_cn@163.com
Received: January 20, 2021 Peer-review started: January 20, 2021 First decision: March 25, 2021 Revised: March 29, 2021 Accepted: April 20, 2021 Article in press: April 20, 2021 Published online: June 26, 2021
Abstract
BACKGROUND
Management of chronic refractory wounds is one of the toughest clinical challenges for surgeons. Because of poor blood supply, less tissue coverage, and easy exposure, the lower leg is a common site for chronic refractory wounds. The current therapeutic regimens often lead to prolonged hospital stay and higher healthcare costs. Concentrated growth factor (CGF) is a novel blood extract that contains various growth factors, platelets, and fibrins to promote wound healing process. However, there has been little research reported on the treatment of lower extremity wounds with CGF.
CASE SUMMARY
A 37-year-old man, without any past medical history, presented an ulcerated chronic wound on his right lower leg. The skin defect exhibited clear boundaries, with a size of 2.0 cm × 3.5 cm. The depth of wound was up to the layer of deep fascia. Staphylococcus aureus was detected by bacterial culture. The final diagnosis was right lower extremity ulcers with infection. Cefathiamidine, silver sulfadiazine, and mupirocin cream were applied to control the infection. CGF gel was prepared from the patient’s blood sample, and was used to cover the wound after thorough debridement. The skin wound was successfully healed after three times of CGF treatment.
CONCLUSION
CGF displays an excellent wound healing promoting effect in patients with lower-extremity chronic refractory wounds.
Core Tip: The effects of the current interventions, such as flap reconstruction, artificial dermis grafting, and negative pressure wound therapy, on chronic refractory wounds may vary among different patients. Concentrated growth factor (CGF) is obtained from the patient’s blood sample, and has a significant amount of growth factors. Here, we report a male patient with lower-extremity wound defects who received CGF treatment. The patient recovered well after three times of CGF treatment. This case highlights the beneficial effect of CGF on chronic wound and provides a novel therapeutic option for lower-extremity refractory wound repair.
